SCHEMBL14973283

SCHEMBL14973283

CCn1ncc(C(=O)O)c1CCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
ASPH Q12797 2/20 0.40
KDM8 Q8N371 2/20 0.40
KDM4E B2RXH2 1/20 0.40
RIOX2 Q8IUF8 1/20 0.40
PLK1 P53350 1/20 0.39
NR4A3 Q92570 1/20 0.39
SORT1 Q99523 1/20 0.39
SRD5A2 P31213 1/20 0.38
HRH3 Q9Y5N1 2/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
GUSB P08236 1/20 0.37
HPSE Q9Y251 1/20 0.37
FABP4 P15090 1/20 0.37
FFAR1 O14842 1/20 0.37
NR3C2 P08235 1/20 0.37
PTGER4 P35408 1/20 0.37
KDM5A P29375 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM5B Q9UGL1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14973133 0.89 ASPH (0.41) MAPTASPHKDM8KDM4ERIOX2
SCHEMBL14972983 0.86 MAPT (0.49) MAPTKDM4ESMN1; SMN2
SCHEMBL14973035 0.85 ASPH (0.42) MAPTASPHKDM8KDM4ERIOX2
SCHEMBL14972977 0.81 PPARA (0.36) MAPTASPHKDM8KDM4ERIOX2
SCHEMBL14973224 0.78 MAPT (0.48) MAPTKDM4ESMN1; SMN2
SCHEMBL14973107 0.73 KDM4E (0.43) MAPTKDM4ENR3C2HDAC1HDAC8
SCHEMBL14973210 0.72 MAPT (0.50) MAPTKDM4ESMN1; SMN2
SCHEMBL6251041 0.72 POLB (0.53) MAPTKDM4ENR4A3POLBSMN1; SMN2
SCHEMBL14973236 0.72 MAPT (0.43) MAPTKDM4ESMN1; SMN2
SCHEMBL2825933 0.71 NPC1 (0.54) MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A MAPT 129/4885ASPH 2766/4885KDM8 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.